MENT (Trestolone) – synthetic androgen frame
Trestolone (7α-methyl-19-nortestosterone, MENT) Population Council 1990s male contraceptive candidate. Synthetic androgen – ~8-10x AR affinity vs testosterone, NOT 17α-alkylated → low hepatotoxicity. Two variants: Acetate (short) and Enanthate (slow). Cross-framed: 19-Nor analog separate entry.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS MENT (TRESTOLONE) – SYNTHETIC ANDROGEN FRAME?
Detailed overview
MENT (Trestolone, 7α-methyl-19-nortestosterone) is a synthetic androgen steroid developed by the Population Council (NYC) in the late 1990s-early 2000s as a male contraceptive candidate (Anderson 1999 PMID 10522995 clinical trial). Anabolic/androgenic activity is ~8-10x testosterone in vitro AR-binding assay (Sundaram 1993 PMID 8489761) – one of the strongest synthetic androgens. The 7α-methyl group inhibits 5α-reductase substrate binding (does NOT convert to DHT → lower scalp-DHT and prostate androgenic activity than testosterone), while the 19-nor structure also shows PROGESTOGENIC ACTIVITY (cross-framed entry character: here in the synthetic androgen frame, separate entry in the 19-Nor framework). Aromatizes via CYP19 to 7α-methylestradiol, which has lower ER affinity than plain E2 → estrogen effect weaker than on Test. NOT 17α-alkylated → low hepatotoxicity. In clinical trials (Population Council 1999-2005) it was tested as a 4-week implant + 8 mg/day sublingual formulation; male contraceptive development was STOPPED after Phase III for financial reasons. In bodybuilding context UGL market offers Acetate ester (Trestolone Acetate, short, ~8h half-life) and Enanthate ester (Trestolone Enanthate, slow, ~5-7 day half-life). WADA-banned year-round.
Mechanism
AR agonist (8-10x Test) + progesterone receptor, 7α-methyl-19-nor-T, aromatizes weakly
Anabolic:Androgenic
~2300:650 (extrapolated in vitro AR-binding)
Half-life
~8 h (Ac), 5-7 d (Enan)
Onset
12-24 h (Ac IM), 48-72 h (Enan IM)
Legal status
Never an Rx, UGL only. Schedule III analog (USA), WADA-banned.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Strong HPTA suppression: endogenous testosterone and sperm production shut down and fertility drops (MENT was originally a male contraceptive candidate precisely for this), with slow and not always complete recovery.
- Prolactin elevation from the 19-nor progestogenic activity: lowered libido, erectile dysfunction (a deca-dick-like effect), nipple discharge and progestogen-driven gynecomastia even when estrogen is low.
- Adverse lipid profile and cardiovascular strain: HDL (good cholesterol) drops moderately to markedly and LDL can rise, raising atherosclerotic and cardiac risk with prolonged use.
- Estrogenic effects from aromatization: MENT aromatizes to 7α-methylestradiol (weaker than plain estradiol but not zero) causing water retention, raised blood pressure and estrogen-driven gynecomastia, especially in the Test-containing mixture variants.
- Mood and psychiatric effects: irritability, aggression, sleep disturbance, and rarely depressive episodes linked to the progestogenic/prolactin activity, with increased risk in those with pre-existing psychiatric predisposition.
- Androgenic skin and hair effects: acne, oily skin, increased body hair and scalp hair loss in predisposed users; MENT does not convert to DHT, so scalp and prostate androgen effects are milder than testosterone but not absent.
- Injection-site reaction (PIP, pain, swelling, inflammation) more pronounced with the short Acetate mixture (lower solubility, frequent, even daily injections) and milder with the slow Enanthate mixture.
- Raised red blood cell count and hematocrit (as with androgens generally) thickening the blood and potentially increasing thrombosis and blood-pressure risk, especially with prolonged higher-dose use.
Contraindications · 7
- Women, especially in or considering pregnancy: MENT is an extremely strong androgen causing rapid and largely irreversible virilization (voice deepening, hair growth, clitoral enlargement) and posing a risk of fetal harm.
- Prolactinoma, hyperprolactinemia or any prolactin-sensitive condition: an absolute contraindication because of the 19-nor progestogenic activity, which worsens existing prolactin problems.
- Pre-existing cardiovascular disease, uncontrolled hypertension or an adverse lipid profile: the androgen's HDL-lowering, fluid-retaining and hematocrit-raising effects increase cardiovascular event risk.
- Current or near-future plans for fatherhood: strong HPTA suppression and shutdown of spermatogenesis markedly reduce fertility, with uncertain recovery.
- Psychiatric predisposition (depression, anxiety, aggression-control disorders): the progestogenic/prolactin and androgenic effects can trigger mood instability and depressive episodes.
- Hormone-sensitive cancer (prostate, breast) or undiagnosed prostate enlargement: androgenic stimulation can promote progression of hormone-dependent tumors and BPH.
- Adolescence / incomplete bone growth, and first-time AAS users: the extreme potency and the unknown, non-standardized MENT/Test ratio of the designer mixture make it especially risky.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
7 alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception
Sundaram K, Kumar N, Bardin CW.
7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men
Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K.
Pharmacokinetics and pharmacodynamics of 7alpha-methyl-19-nortestosterone after intramuscular administration in healthy men
Suvisaari J, Sundaram K, Noé G et al.
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement
Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S.
Effects of androgenic-anabolic steroids in athletes
Hartgens F, Kuipers H.
Telegram
Have a question about MENT (Trestolone) – synthetic androgen frame?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.